https://www.selleckchem.com/pr....oducts/gusacitinib.h
The two ViMAC patients without re-intervention had persistent anemia and died within 6months. Both MViV and MViR patients with hemolysis did not have PVL but had turbulent flow from left ventricular outflow tract narrowing and their hemolysis was self-limited. Hemolysis occurs with greater frequency and increased clinical severity after ViMAC as compared to MViV or MViR and is likely related to increased incidence of PVL. These findings demonstrate the need to investigate novel strategies that can reduce the burden of hemolysis with
Мне нравится
Комментарий
Перепост
